Drugs / MP1032
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04932941 | Oct 2021 → Jul 2022 | COVID-19 | MetrioPharm AG | Completed | Missed primary |
| Phase 2 | NCT03706209 | Feb 2018 → Jun 2019 | psoriasis | MetrioPharm AG | Completed | Missed primary |
| Phase 2 | NCT02908347 | May → Dec 2016 | psoriasis | MetrioPharm AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 21
| Date | Issuer | Release |
|---|---|---|
| 2025-07-29 | MetrioPharm AG | Regulatory MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy metriopharm.com ↗
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). |
| 2024-01-31 | MetrioPharm AG | Results MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19 metriopharm.com ↗
Patients treated with MP1032 (n=86) exhibited a lower mortality compared to those receiving placebo + SoC (n=45). |
| 2023-10-25 | MetrioPharm AG | Regulatory MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA metriopharm.com ↗
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy. |
| 2023-05-30 | MetrioPharm AG | Regulatory MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy metriopharm.com ↗
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy. |
| 2022-12-08 | MetrioPharm AG | Results MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients metriopharm.com ↗
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, today announced topline data of its CT05 Phase IIa double-blind placebo-controlled study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients. |
| 2021-04-08 | MetrioPharm AG | Results Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032 metriopharm.com ↗
MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, reports positive results from two long-term preclinical toxicology studies in the rat and the dog. |
| 2020-11-05 | MetrioPharm AG | Results MetrioPharm Announces Publication of Successful MP1032 Preclinical Data in COVID-19 metriopharm.com ↗
MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, announces the publication of preclinical data showing its lead compound MP1032 could be a promising option for prevention and treatment of the SARS-CoV-2-induced cytokine storm. |
| 2020-04-08 | MetrioPharm AG | Results MetrioPharm Successfully Completes Study in COPD Model metriopharm.com ↗
MetrioPharm AG, a pharmaceutical development company, reports positive data from a preclinical study in a model for COPD (Chronic Obstructive Pulmonary Disease). |
| 2019-10-16 | MetrioPharm AG | Results MetrioPharm AG Phase II Data in Psoriasis Show Dose-Response, Disease Modifying Activity and Outstanding Safety Profile metriopharm.com ↗
MetrioPharm AG, a clinical stage biopharmaceutical company, reports positive results from its recently completed Phase II dose finding study of MP1032 in psoriasis patients. |
| 2018-10-09 | MetrioPharm AG | Results MetrioPharm Announces Presentation of Preclinical Data on MP1032 in Multiple Sclerosis Therapy at ECTRIMS Congress 2018 metriopharm.com ↗
Preclinical data suggest that MP1032 may have this potential. |
| 2018-06-26 | MetrioPharm AG | Results MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at the 5th WPPAC in Stockholm metriopharm.com ↗
After only six weeks of treatment, MP1032 reduced the PASI scores by about 28 % in patient |
| 2018-05-29 | MetrioPharm AG | Results MetrioPharm Announces Data Presentation on the Mechanism of Action of MP1032 at the 19th SFRRI Meeting in Lisbon metriopharm.com ↗
We used a specific technique, the so called ultra-weak photon emission imaging, to monitor ROS production in inflamed joints and demonstrated that MP1032 acts directly and only at the side of inflammation. |
| 2017-09-07 | MetrioPharm AG | Regulatory MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to South Korea metriopharm.com ↗
MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in South Korea. |
| 2017-03-14 | MetrioPharm AG | Results MetrioPharm Announces Positive Top Line Results from a Phase IIa Study in Moderate-to-Severe Psoriasis with its Oral Lead Compound MP1032 metriopharm.com ↗
MetrioPharm AG, a biotech company developing small molecule immune modulators for autoimmune and other inflammatory diseases, today announces positive top line results from its phase IIa trial with its proprietary drug compound MP1032 in patients with moderate-to-severe plaque psoriasis. |
| 2016-03-29 | MetrioPharm AG | Regulatory New basic patent has been granted for MP1032 metriopharm.com ↗
MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries. |
| 2015-12-16 | MetrioPharm AG | Results Phase I successfully completed metriopharm.com ↗
MetrioPharm AG today announced positive results for all end points of its placebo controlled phase Ib clinical trial of the company's lead drug MP1032. |
| 2015-10-19 | MetrioPharm AG | Regulatory Second part of Phase I Safety Study cleared by authorities metriopharm.com ↗
Based on the fact that in the single-dose part of Phase I MP1032 had not shown any adverse reactions or tolerability issues, BfArM recently gave the go-ahead for the multiple-dose part of Phase I without any additional safety restrictions. |
| 2015-07-15 | MetrioPharm AG | Results Single-dose part of MP1032’s first-in-man clinical trial successful metriopharm.com ↗
MetrioPharm AG announces results of the single-dose part of its Phase I first-in-man clinical trial with its lead compound MP1032. |
| 2015-04-07 | MetrioPharm AG | Regulatory MetrioPharm announces regulatory approval to initiate clinical development of MP1032 metriopharm.com ↗
MetrioPharm AG has received approval to commence its phase 1 clinical trial with MP1032 from the German regulatory authority (BfArM). |
| 2014-11-20 | MetrioPharm AG | Regulatory MetrioPharm AG has submitted the phase I investigational new drug application for MP1032 metriopharm.com ↗
MetrioPharm AG has submitted the phase I investigational new drug application for its lead compound MP1032 to BfArM (German Federal Institute for Drugs and Medical Devices). |
| 2014-01-30 | MetrioPharm AG | Results MetrioPharm Milestones – on the route to a new drug metriopharm.com ↗
The most important outcome was MP1032's superior safety profile as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted throughout the past year. |
All press releases naming this drug 30 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP1032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04932941 ↗ |
| Route | Oral | “100 mg MP1032 or placebo orally twice daily for 42 days” NCT02908347 ↗ |